Evidence map›Paper›PMID 42463654›Full record

ArticleNature communications2026

Triple IFN pathway deficiency sensitizes mice to human respiratory virus infection independent of human viral receptor expression.

Qinghong Fan, Meifang Pan, Mengling Jiang, Chengqian Feng, Jianping Cui, Jun Zhang, Shiquan Liang, Yaping Wang, Jingrong Shi, Rui Li and 8 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qinghong Fan *Guangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Meifang Pan *Guangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Mengling Jiang *Guangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Chengqian Feng *Guangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Jianping Cui *Guangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Jun Zhang *Guangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Shiquan LiangDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Yaping WangGuangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Jingrong ShiGuangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0003-3019-3272
Rui LiGuangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Wei ZhangDepartment of Respiratory and Critical Care Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Liqiang FengChina-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.ORCID http://orcid.org/0000-0001-6811-2074
Haisheng YuGuangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0002-1757-1411
Yi-Ping LiInstitute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, China.ORCID http://orcid.org/0000-0001-6011-3101
Fengyu HuGuangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Xiaoping TangGuangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0002-5067-659X
Hongbo GuoDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Feng LiGuangzhou Key Laboratory of Clinical Pathogen Research for Infectious Diseases, Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China. gz8h_lifeng@126.com.ORCID http://orcid.org/0000-0003-3169-6349

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferon (IFN) pathways form the innate barrier against viral invasion and partial deficiency in these pathways allows human virus infection. Whether a complete IFN pathway deficiency could confer the susceptibility to human viral infection independent of expressing the human viral receptor remains unknown. We develop an innate immunity severely deficient mouse model, designated AGL, which features one-step knock-out of the IFNAR, IFNGR and IFNLR. The AGL mice become susceptible to diverse representative human respiratory viruses, including adenovirus type 55 (HAdV-55; double-stranded DNA), human monkeypox virus (MPXV) clade IIb (double-stranded DNA), parainfluenza virus (PIV; negative-sense single-stranded RNA), and the clinically isolated SARS-CoV-2 delta variant (positive-sense single-stranded RNA). Our results suggest that the type III IFN pathway constitutes a backup layer of antiviral frontline beneath the type I and II IFN pathways. In addition, proof-of-concept studies testing MPXV and PIV antivirals highlight the translational value of AGL mice. The AGL mice, as a universal model, substantially enhance the ability to investigate both emerging and established viruses without the need for tailored mouse models.

Indexed as

InterferonsReceptors, InterferonReceptors, VirusRespiratory Tract InfectionsAnimalsDisease Models, AnimalFemaleHumansImmunity, InnateInterferon gamma ReceptorMiceMice, Inbred C57BLMice, KnockoutReceptor, Interferon alpha-betaSARS-CoV-2Signal TransductionIfnar1 protein, mouseInterferon gamma ReceptorInterferonsReceptor, Interferon alpha-betaReceptors, InterferonReceptors, Virus

Identifiers

PMID42463654
PMCPMC13518883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.